Location: San Francisco

Disease Area: Oncology

R&D Focus: Development of therapeutics that target myeloid cells in the tumor microenvironment to enhance the immune system's anti-tumor response, as well as platform technologies for discovery of novel antibodies and targets in the tumor microenvironment.

Disease Area: Oncology

Founding Date: 2015

Founders: Max Krummel (UCSF) and Sachdev Sidhu (University of Toronto, formerly Genentech)

Board of Directors: Leon Chen (OrbiMed); Carol Gallagher (NEA) Steven James (Pionyr CEO); Max Krummel (UCSF); Mike Powell (Sofinnova); Joshua Resnick (SV Health Investors)

No. of Employees: 15

Investors: NEA, Mission Bay Capital, Osage University Partners, Vida Ventures, Sofinnova, OrbiMed, SV Health Investors

Total financing to date: $71m

Intellectual Property: Patent portfolio for its targets, as well as exclusive license to a UCSF patent family based on Max Krummel's IO discoveries.

Pionyr Maps Tumor Microenvironment, Plans 'Surgical' Strikes

More from Start-Ups & SMEs

More from Business